Site icon pharmaceutical daily

ArsenalBio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–#ArsenalBioArsenalBio, a privately held programmable cell therapy company focused on building advanced CAR T therapies for solid tumors, today announced that Company leadership will participate in two upcoming virtual investor conferences:

About ArsenalBio

ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients. To learn more, visit www.arsenalbio.com and follow us on Twitter @ArsenalBio, LinkedIn and Facebook.

Contacts

Heidi Chokeir, Ph.D.

Canale Communications

619-203-5391

heidi.chokeir@canalecomm.com

Exit mobile version